Exane Derivatives’s Mandiant, Inc. Common Stock MNDT Stock Holding History

Exane Derivatives’s Portfolio MNDT Stock Details MNDT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1	Closed	-$17	–	741
2019 Q1	$17	Hold	1	–	–	﹤0.01%	618
2018 Q4	$16	Hold	1	–	–	﹤0.01%	661
2018 Q3	$17	Hold	1	–	–	﹤0.01%	681
2018 Q2	$15	Sell	1 -3,975	-100%	-$69.1K	﹤0.01%	674
2018 Q1	$67.2K	Sell	3,976 -14,136	-78%	-$228K	0.01%	334
2017 Q4	$257K	Buy	18,112 +8,112	+81%	+$123K	0.04%	219
2017 Q3	$168K	Buy	+10,000	New	+$154K	0.03%	208

Other funds holding MNDT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Shapiro Capital Management Atlanta, Georgia $1.65B AUM 26.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Exane Derivatives's MNDT Position: Q2 2019 in Review

Exane Derivatives sold out of Mandiant, Inc. Common Stock (MNDT) in Q2 2019, closing a stake of 1 share — an estimated $17 sold.

Exane Derivatives first reported a position in MNDT in Q3 2017 and held it in 7 quarters. The position peaked at $257K in Q4 2017. 303 funds tracked by Wall St. Rank hold MNDT as of Q2 2019.

Exane Derivatives reported no remaining Mandiant, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
Exane Derivatives sold 1 Mandiant, Inc. Common Stock share in Q2 2019, an estimated $17.
Exane Derivatives first reported a position in Mandiant, Inc. Common Stock in Q3 2017 and held it in 7 quarters.
Exane Derivatives's Mandiant, Inc. Common Stock position peaked at $257K in Q4 2017.
303 funds tracked by Wall St. Rank held Mandiant, Inc. Common Stock as of Q2 2019.

Based on Exane Derivatives's 13F filing for Q2 2019, filed 12 Jul 2019.